Akebia Therapeutics (AKBA) Misses Q4 EPS by 32c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.79), $0.32 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $69.56 million versus the consensus estimate of $93.15 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Goldman Regional Director in US Adjusts List of Top Names
• Baird Reiterates Outperform Rating on Nike (NKE)
• Corona-maker Constellation Brands beats estimates, shares jump 2%